Results 11 to 20 of about 280,575 (305)

Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer

Therapeutics and Clinical Risk Management, 2015
Katsuhiko Shimizu, Riki Okita, Shinsuke Saisho, Takuro Yukawa, Ai Maeda, Yuji Nojima, Masao Nakata Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Japan Background: Adjuvant chemotherapy after the complete resection of non ...
Shimizu K, Okita R, Saisho S, Yukawa T, Maeda A, Nojima Y, Nakata M   +6 more
doaj   +1 more source

Adjuvant chemotherapy

European Journal of Cancer Supplements, 2013
The mean SPARC, FOXP3, CD8 or CD45RO expression levels in patients who did, or did not, receive adjuvant chemotherapy in stage II and III CRC. SPARC was significantly greater in patients with stage III CRC who did not require chemotherapy, whilst FOXP3 ...
David B. Abrams, J. Rick Turner, Linda C. Baumann, Alyssa Karel, Susan E. Collins, Katie Witkiewitz, Terry Fulmer, Molly L. Tanenbaum, Persis Commissariat, Elyse Kupperman, Rachel N. Baek, Jeffrey S. Gonzalez, Nicole Brandt, Rachel Flurie, Jennifer Heaney, Christopher Kline, Linda Carroll, Jane Upton, Patrícia Cardoso Buchain, Adriana Dias Barbosa Vizzotto, Alexandra Martini de Oliveira, Tania C. T. Ferraz Alves, Quirino Cordeiro, Lorenzo Cohen, M. Kay Garcia, Amy Jo Marcano-Reik, Siqin Ye, Yori Gidron, Marc D. Gellman, M. Bryant Howren, Manjunath Harlapur, Daichi Shimbo, Keisuke Ohta, Naoya Yahagi, Elizabeth Franzmann, Abanish Singh, Linda C. Baumann, Alyssa Karel, Debra Johnson, Benjamin L. Clarke, Debra Johnson, Rachel Millstein, Karen Niven, Karen Niven, Eleanor Miles, J. Rick Turner, Barbara Resnick, Yori Gidron, Carter A. Lennon, Kelly S. DeMartini, Kristin L. MacGregor, Susan E. Collins, Megan Kirouac, J. Rick Turner, Abanish Singh, Yori Gidron, Yoshiharu Yamamoto, Urs M. Nater, Nicole Nisly, Debra Johnson, Derek Johnston, Ydwine Zanstra, Derek Johnston, Youngmee Kim, Della Matheson, Brooke McInroy, Christopher France, Shin Fukudo, Emiko Tsuchiya, Yoko Katayori, Martin Deschner, Norman B. Anderson, Chad Barrett, Mark A. Lumley, Lindsay Oberleitner, Stephan Bongard, Siqin Ye, Amy Jo Marcano-Reik, Seth Hurley, Seth Hurley, Anna Maria Patino-Fernandez, Anna C. Phillips, Tatsuo Akechi, Anna C. Phillips, Amy Jo Marcano-Reik, Nicole Brandt, Rachel Flurie, Sarah Aldred, Kim Lavoie, Manjunath Harlapur, Daichi Shimbo, Kate L. Jansen, Katherine T. Fortenberry, Molly S. Clark, Rachel Millstein, Toru Okuyama, William Whang, Mustafa Al’Absi, Bingshuo Li, Yori Gidron, J. Rick Turner, Elizabeth R. Pulgaron, Diana Wile, Linda C. Baumann, Alyssa Karel, Beth Schroeder, Mary C. Davis, Alex Zautra, Shannon L. Stark, William Whang, Ana Victoria Soto, Yori Gidron, Anthony J. Wheeler, Scott DeBerard, Josh Allen, Akihisa Mitani, Akihisa Mitani, Elizabeth R. Pulgaron, Akihisa Mitani, Jennifer Carter, William Whang, Beth Schroeder, Angela M. Hicks, Carolyn Korbel, Austin S. Baldwin, Kevin S. Spink, Darren Nickel, Michael Richter, Rex A. Wright, Julian F. Thayer, Michael Richter, Rex A. Wright, Deborah J. Wiebe   +132 more
core   +4 more sources

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis

Frontiers in Oncology, 2022
BackgroundFor rectal cancer, it remains unclear how to incorporate tumor response to neoadjuvant chemoradiotherapy (nCRT) when deciding whether to give adjuvant chemotherapy.
Yu-Hsuan Kuo, Yu-Hsuan Kuo, Yun-Tzu Lin, Chung-Han Ho, Chung-Han Ho, Chia-Lin Chou, Chia-Lin Chou, Li-Chin Cheng, Chia-Jen Tsai, Wei-Ju Hong, Yi-Chen Chen, Ching-Chieh Yang, Ching-Chieh Yang   +12 more
doaj   +1 more source

Differences in the performance of adjuvant chemotherapy between hemodialysis and nonhemodialysis patients

Cancer Medicine, 2023
Background The survival of hemodialysis (HD) patients with cancer is poor, which may be caused by undertreatment due to renal dysfunction. Particularly, adjuvant chemotherapy after surgery may be considered optional because of its preventive nature. This
Taisuke Ishii, Tomone Watanabe, Takahiro Higashi   +2 more
doaj   +1 more source

Whether Patients With Stage Ⅱ/Ⅲ Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data

Frontiers in Pharmacology, 2022
Objective: This study used model analysis to clarify the benefits and risks of postoperative adjuvant chemotherapy compared with surgery alone in patients with stage II/III colorectal cancer.Methods: Clinical trials involving patients with stage II/III ...
Sijie Zha, Ting Li, Qingshan Zheng, Lujin Li   +3 more
doaj   +1 more source

Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort

BMC Cancer, 2022
Background There is no clear consensus on the benefits of adjuvant chemotherapy for tumor-node-metastasis (TNM) stage T1 (T1N0M0) breast cancer (BC). Our study investigated the effects of adjuvant chemotherapy on T1N0M0 BC patients.
Kaiwen Shen, Longdi Yao, Jingyuan Zhu, Ximing Gu, Jie Wang, Wei Qian, Zhijian Zheng, Deyuan Fu, Song Wu   +8 more
doaj   +1 more source

Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National university hospital experience

International Brazilian Journal of Urology, 2015
Objectives: The objective of this study was to update the long-term outcome in the treatment of locally advanced upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) regarding the role of adjuvant chemotherapy.
Hyung Suk Kim, Joong Sub Lee, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku   +5 more
doaj   +1 more source

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients : analysis of >4,500 patients from four German randomized breast cancer trials [PDF]

, 2008
Introduction: Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases.
Kümmel, Sherko, Sibylle Loibl, Gunter von Minckwitz, Kuemmel, Sherko, Valentina Nekljudova, Marion Kiechle, Elling, Dirk, Holm Eggemann, Harald Sommer, Janni, Wolfgang, Sommer, Harald, Wolfgang Janni, Loibl, Sibylle, Nadia Harbeck, Manfred Kaufmann, Harbeck, Nadia, Nekljudova, Valentina, Minckwitz, Gunter von, Sherko Kümmel, Kiechle, Marion, Kaufmann, Manfred, Eggemann, Holm, Dirk Elling   +22 more
core   +1 more source

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation [PDF]

, 2006
Objectives: To assess the clinical and cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/ leucovorin (5-FU/LV), and capecitabine monotherapy (within their licensed indications), as adjuvant therapies in the treatment of ...
Tappenden, P., P Tappenden, Sutcliffe, P., P Sutcliffe, S Paisley, S Eggington, Sutcliffe, P. (Paul), Paisley, S., Eggington, S., A Pandor, Egginton, S., Pandor, A.   +11 more
core   +1 more source

Adjuvant chemotherapy [PDF]

Cancer, 1978
In this brief presentation, an attempt was made to illustrate why it is not possible to carry over chemotherapeutic trial results from one animal cancer to another or one human cancer to another without corrections for differences in (a) staging, (b) dose response, and (c) tumor regrowth rates.
openaire   +2 more sources